Stockreport

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio, Inc.  (GRI) 
PDF Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline [Read more]